Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM, Weber DR, DMD Care Considerations Working Group (2018). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17(3):251–267. https://doi.org/10.1016/S1474-4422(18)30024-3

Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifirò G (2020) Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis 15(1):141. https://doi.org/10.1186/s13023-020-01430-8

Article  PubMed  PubMed Central  Google Scholar 

Ferizovic N, Summers J, de Zárate IBO, Werner C, Jiang J, Landfeldt E, Buesch K (2022) Prognostic indicators of disease progression in Duchenne muscular dystrophy: a literature review and evidence synthesis. PLoS ONE 17(3):e0265879. https://doi.org/10.1371/journal.pone.0265879

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verhaart IEC, Aartsma-Rus A (2019) Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol 15(7):373–386. https://doi.org/10.1038/s41582-019-0203-3

Article  PubMed  Google Scholar 

Ma J, McMillan HJ, Karagüzel G, Goodin C, Wasson J, Matzinger MA, DesClouds P, Cram D, Page M, Konji VN, Lentle B, Ward LM (2017) The time to and determinants of first fractures in boys with Duchenne muscular dystrophy. Osteoporos Int 28(2):597–608. https://doi.org/10.1007/s00198-016-3774-5

Article  CAS  PubMed  Google Scholar 

Wells E, Kambhampati M, Damsker JM, Gordish-Dressman H, Yadavilli S, Becher OJ, Gittens J, Stampar M, Packer RJ, Nazarian J (2017) Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor. Oncotarget 8(6):9366–9374. https://doi.org/10.18632/oncotarget.14070

Liu X, Wang Y, Gutierrez JS, Damsker JM, Nagaraju K, Hoffman EP, Ortlund EA (2020) Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA 117(39):24285–24293. https://doi.org/10.1073/pnas.2006890117

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith EC, Conklin LS, Hoffman EP, Clemens PR, Mah JK, Finkel RS, Guglieri M, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, Kerchner L, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, Gordish-Dressman H, … CINRG VBP15 and DNHS Investigators (2020) Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. PLoS Med 17(9):e1003222. https://doi.org/10.1371/journal.pmed.1003222

Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavroudis PD, Schwartz BD, Mengle-Gaw LJ, Smith EC, Mah JK, Guglieri M, Nevo Y, Kuntz N, McDonald CM, Tulinius M, Ryan MM, Webster R, Castro D, Finkel RS, Smith AL, Morgenroth LP, … Clemens PR (2018) Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacol Res 136:140–150. https://doi.org/10.1016/j.phrs.2018.09.007

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, … Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clin Res Ed) 372: n71. https://doi.org/10.1136/bmj.n71

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2024) Cochrane handbook for systematic reviews of interventions version 6.2 (updated Feb. 2021). Cochrane, 2024. Available from www.training.cochrane.org/handbook

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5(1):210. https://doi.org/10.1186/s13643-016-0384-4

Article  PubMed  PubMed Central  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, … Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clin Res Ed) 366:l4898. https://doi.org/10.1136/bmj.l4898

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, … Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Clin Res Ed) 355:i4919. https://doi.org/10.1136/bmj.i4919

NIH. Quality assessment tool for before-after (Pre-Post) studies with no control group. Study Quality Assessment Tools | NHLBI, NIH. Available at: https://cdn-links.lww.com/permalink/mao/b/mao_00_00_2022_05_12_oehlandt_on-21-849_sdc2.pdf

McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, Atkinson L, Reha A, Hirawat S, Miller LL (2010) The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 41(4):500–510. https://doi.org/10.1002/mus.21544

Article  PubMed  Google Scholar 

Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ (1981) Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 4(3):186–197. https://doi.org/10.1002/mus.880040304

Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J, Manzur A, Muntoni F, North Star Clinical Network for Paediatric Neuromuscular Disease (2012) Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int 17(2):101–109. https://doi.org/10.1002/pri.520

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res Ed) 315(7109):629–634. https://doi.org/10.1136/bmj.315.7109.629

Article  CAS  Google Scholar 

Mah JK, Clemens PR, Guglieri M, Smith EC, Finkel RS, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, McDonald CM, Damsker JM, Schwartz BD, Mengle-Gaw LJ, Jackowski S, Stimpson G, Ridout DA, Ayyar-Gupta V, Baranello G, … NorthStar UK Network and CINRG DNHS Investigators (2022) Efficacy and safety of vamorolone in duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial. JAMA Netw Open 5(1):e2144178. https://doi.org/10.1001/jamanetworkopen.2021.44178

Hoffman EP, Schwartz BD, Mengle-Gaw LJ, Smith EC, Castro D, Mah JK, McDonald CM, Kuntz NL, Finkel RS, Guglieri M, Bushby K, Tulinius M, Nevo Y, Ryan MM, Webster R, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Siener C, … Cooperative International Neuromuscular Research Group (2019) Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology 93(13): e1312–e1323. https://doi.org/10.1212/WNL.0000000000008168

Guglieri M, Clemens PR, Perlman SJ, Smith EC, Horrocks I, Finkel RS, Mah JK, Deconinck N, Goemans N, Haberlova J, Straub V, Mengle-Gaw LJ, Schwartz BD, Harper AD, Shieh PB, De Waele L, Castro D, Yang ML, Ryan MM, McDonald CM, … Hoffman EP (2022) Efficacy and safety of vamorolone vs placebo and prednisone among boys with duchenne muscular dystrophy: a randomized clinical trial. JAMA Neurol 79(10):1005–1014. https://doi.org/10.1001/jamaneurol.2022.2480

Rahimov F, Kunkel LM (2013) The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy. J Cell Biol 201(4):499–510. https://doi.org/10.1083/jcb.201212142

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barnes PJ (2006) Corticosteroid effects on cell signalling. Eur Respir J 27(2):413–426. https://doi.org/10.1183/09031936.06.00125404

Article  CAS  PubMed  Google Scholar 

Oakley RH, Cidlowski JA (2013) The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol 132(5):1033–1044. https://doi.org/10.1016/j.jaci.2013.09.007

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heier CR, Damsker JM, Yu Q, Dillingham BC, Huynh T, Van der Meulen JH, Sali A, Miller BK, Phadke A, Scheffer L, Quinn J, Tatem K, Jordan S, Dadgar S, Rodriguez OC, Albanese C, Calhoun M, Gordish-Dressman H, Jaiswal JK, Connor EM, … Nagaraju K (2013) VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med 5(10):1569–1585. https://doi.org/10.1002/emmm.201302621

Reeves EKM, Hoffman EP, Nagaraju K, Damsker JM, McCall JM (2013) VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorg Med Chem 21(8):2241–2249. https://doi.org/10.1016/j.bmc.2013.02.009

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heier CR, Yu Q, Fiorillo AA, Tully CB, Tucker A, Mazala DA, Uaesoontrachoon K, Srinivassane S, Damsker JM, Hoffman EP, Nagaraju K, Spurney CF (2019) Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance 2(1):e201800186. https://doi.org/10.26508/lsa.201800186

Sreetama SC, Chandra G, Van der Meulen JH, Ahmad MM, Suzuki P, Bhuvanendran S, Nagaraju K, Hoffman EP, Jaiswal JK (2018) Membrane stabilization by modified steroid offers a potential therapy for muscular dystrophy due to Dysferlin deficit. Mol Ther 26(9):2231–2242. https://doi.org/10.1016/j.ymthe.2018.07.021

Article  CAS  PubMed  PubMed Central  Google Scholar 

Werneck LC, Lorenzoni PJ, Ducci RD, Fustes OH, Kay CSK, Scola RH (2019) Duchenne muscular dystrophy: an historical treatment review. Arq Neuropsiquiatr 77(8):579–589. https://doi.org/10.1590/0004-282X20190088

Article  PubMed  Google Scholar 

Mah JK (2016) Current and emerging treatment strategies for Duchenne muscular dystrophy. Neuropsychiatr Dis Treat 12:1795–1807. https://doi.org/10.2147/NDT.S93873

Article  PubMed  PubMed Central  Google Scholar 

Arora H, Willcocks RJ, Lott DJ, Harrington AT, Senesac CR, Zilke KL, Daniels MJ, Xu D, Tennekoon GI, Finanger EL, Russman BS, Finkel RS, Triplett WT, Byrne BJ, Walter GA, Sweeney HL, Vandenborne K (2018) Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history. Muscle Nerve 58(5):631–638. https://doi.org/10.1002/mus.26161

Article  CAS  PubMed  PubMed Central  Google Scholar 

McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, Clemens PR, Hoffman EP, Cnaan A, Gordish-Dressman H, Investigators CINRG (2018) Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet (London, England) 391(10119):451–461. https://doi.org/10.1016/S0140-6736(17)32160-8

Article  CAS  PubMed  Google Scholar 

Shieh PB, Elfring G, Trifillis P, Santos C, Peltz SW, Parsons JA, Apkon S, Darras BT, Campbell C, McDonald CM, Members of the Ataluren Phase IIb Study Group, Members of the Ataluren Phase IIb Study Clinical Evaluator Training Group, Members of the ACT DMD Study Group, & Members of the ACT DMD Clinical Evaluator Training Group (2021) Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy. J Comp Eff Res 10(18): 1337–1347. https://doi.org/10.2217/cer-2021-0018

Pye SR, Ward KA, Cook MJ, Laurent MR, Gielen E, Borghs H, Adams JE, Boonen S, Vanderschueren D, Wu FC, O’Neill TW (2017) Bone turnover predicts change in volumetric bone density and bone geometry at the radius in men. Osteoporos Int 28(3):935–944. https://doi.org/10.1007/s00198-016-3816-z

Article  CAS  PubMed  Google Scholar 

Babadjanova G, Allolio B, Vollmer M, Reincke M, Schulte HM (1996) Comparison of the pharmacodynamic effects of deflazacort and prednisolone in healthy subjects. Eur J Clin Pharmacol 51(1):53–57. https://doi.org/10.1007/s002280050160

Article  CAS  PubMed  Google Scholar 

Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaissé JM (2003) The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18(5):859–867. https://doi.org/10.1359/jbmr.2003.18.5.859

Article  CAS  PubMed  Google Scholar 

Sivapalan P, Jørgensen NR, Mathioudakis AG, Eklöf J, Lapperre T, Ulrik CS, Andreassen HF, Armbruster K, Sivapalan P, Janner J, Godtfredsen N, Weinreich UM, Nielsen TL, Seersholm N, Wilcke T, Schuetz P, Klausen TW, Marså K, Vestbo J, Jensen JU (2020) Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial. Respir Res 21(1):263. https://doi.org/10.1186/s12931-020-01531-9

Article  CAS